



## Image Quiz

What's the cause of a dog's bilateral submandibular draining tracts? **260**

## Journal Scan

- ▶ Investigating feline audiogenic reflex seizures **256**
- ▶ Comparing two spay techniques in cats **258**

## At-home diabetic monitoring

Advice on helping clients achieve accurate results, charging appropriately **264**

## Toxic troubles for rabbits

A parasiticide with life-threatening effects **270**

## Idea Exchange

- ▶ Install cat doors to keep trash out of sight **282**
- ▶ Use rubber bands to store BP cuffs **282**


# A diagnosis is at *your* **command**

How simply asking a dog to “sit”—among other diagnostic evaluations—can help you differentiate between bad hips and bad knees

**p275**



UBM



# Delivering new beginnings for pets and the families who love them

Our name not only means new beginning, it defines our approach to developing therapeutic solutions for the unmet and underserved medical needs in pets. By taking advances from human science, Aratana Therapeutics is bringing innovative prescription medicines to veterinarians. We deliver solutions for medical conditions that currently have few, if any, treatment options. Aratana has more than 18 therapeutics in our development pipeline for cancer, pain, inappetence, viral diseases and allergy that may help to extend and improve the quality of lives for pets. And that's just the beginning.

**Find out more at [www.aratana.com](http://www.aratana.com).**

## See us at these upcoming conferences to learn more:

ACVS Symposium, Oct. 2015, Nashville; NAVC, Jan. 2016, Orlando; VOS, Feb. 2016, Big Sky, MT; WVC, March 2016, Las Vegas; AAHA, March 2016, Austin, TX; ACVIM, June 2016, Denver; IVECCS, Sept. 2016, Grapevine, TX; and VCS Annual Conference, Oct. 2016, Orlando.



# Veterinary medicine®

Essential medicine for exemplary patient care

## Mission

*Veterinary Medicine* is a peer-reviewed journal dedicated to providing concise, credible, and essential information on the most common and crucial clinical problems seen in companion-animal practice.

## Editorial Advisory Board

Leading specialists who direct our content and ensure our editorial quality and integrity

Joseph W. Bartges, DVM, PhD, DACVIM, DACVN

David S. Bruyette, DVM, DACVIM

Barret Bulmer, DVM, MS, DACVIM

John Ciribassi, DVM, DACVB

Timothy M. Fan, DVM, DACVIM

Juliet R. Gionfriddo, DVM, MS, DACVO

Karen A. Moriello, DVM, DACVD

Jennifer Wardlaw, DVM, DACVS

## Practitioner Advisory Board

Progressive practitioners who keep our content practical, timely, and relevant

Mili Bass, DVM, DABVP

Robin Downing, DVM, DAAPM, DACVSMR, CVPP, CCRP

Corey Entriiken, DVM

Wayne L. Hunthausen, DVM

Thomas McCoy, DVM

Melissa M. Mckendry, DVM, DABVP

Fred L. Metzger Jr., DVM, DABVP

Robert M. Miller, DVM

Gary D. Norsworthy, DVM, DABVP

R. Wayne Randolph, VMD

Michael H. Riegger, DVM, DABVP

David Robbins, DVM

Philip VanVranken, DVM

Laura L. Wade, DVM, DABVP



## Content Group

Editor/Medicine Channel Director | Mindy Valcarcel  
mvalcarcel@advanstar.com

Medical Editor | Heather Lewellen, DVM

Content Manager | Adrienne Wagner

Senior Content Specialists | Alison Fulton | Jennifer Gaumnitz

Assistant Content Specialists | Katie James | Matthew Kenwright

Technical Editor | Jennifer Vossman, RVT

Consulting Technical Editor | Avi Blake, DVM

Digital Content Director | Jessica Zemler

Digital Design Director | Ryan Kramer

Art Director | Shawn Stigsell

Multimedia Contributor | Troy Van Horn

## UBM Life Sciences, Veterinary

Vice President & Managing Director | Becky Turner Chapman

Group Content Director | Mamette Falley

Medical Director | Theresa Entriiken, DVM

Vice President, Digital Product Management | Mark Eisler

Director, Marketing | Brenda Andresen

Director, The CVC Group | Peggy Shandy Lane

## Sales Group

Sales Director | David Doherty

Senior Account Managers, Advertising  
Terry Reilly | Heather Townsend | Angie Homann

Account Manager, Advertising | Angela Paulovcin

Sales and Projects Coordinator | Anne Belcher

Books/Resource Guides | Maureen Cannon  
(440) 891-2742

List Rental Sales | Tamara Phillips  
(440) 891-2773, tphilips@advanstar.com

## UBM Advanstar

Chief Executive Officer | Joe Loggia

Executive Vice President & Senior Managing Director | Tom Ehardt

Executive Vice President | Georgiann DeCenzo

Executive Vice President | Chris DeMoulin

Executive Vice President, Business Systems | Rebecca Evangelou

Executive Vice President, Human Resources | Julie Molleston

Executive Vice-President, Strategy & Business Development | Mike Alic

Senior Vice President | Tracy Harris

Vice-President, Managing Director Pharm/Science Group | Dave Esola

Vice President, Legal | Michael Bernstein

Vice President, Media Operations | Francis Heid

Vice-President, Treasurer & Controller | Adele Hartwick

**Subscriber Services:** Call (800) 815-3400 in the United States, or (888) 527-7008 or (218) 740-6477 in Canada; fax (218) 740-6417; or write to: *Veterinary Medicine*, 131 W. 1st St., Duluth, MN 55802-2065. If you are unable to connect with the 800 numbers, email [fulfill@superfill.com](mailto:fulfill@superfill.com). **Reprint Services:** Call 1-877-652-5295 ext. 121 or email [bkolb@wrightsmedia.com](mailto:bkolb@wrightsmedia.com). Outside US, UK, direct dial: 281-419-5725 ext. 121 **Back Issues:** Individual copies are available for one year; to order, call (800) 598-6008. Permissions/International Licensing. Call Maureen Cannon at (440) 891-2742. **List Sales:** Please contact List Account Executive Renée Schuster at (440) 891-2613. **Editorial Offices:** Write to 8033 Flint, Lenexa, KS 66214; or call (913) 871-3800. **Visit our websites:** [dvm360.com](http://dvm360.com); [theccvc.com](http://theccvc.com); [industrymatter.com](http://industrymatter.com).

Veterinary Medicine (ISSN 8750-7943 print; ISSN 1939-1919 online) is published monthly by UBM Life Sciences, 131 West First St., Duluth, MN 55802-2065. One year subscription rates: \$60 in the United States and Possessions; \$72 in Canada and Mexico; \$97 in all other countries. Single issue orders: \$18 in the United States and Possessions; \$22 in Canada and Mexico; \$24 in all other countries. Periodicals postage paid at Duluth, MN 55806 and additional mailing offices. POSTMASTER: Please send address changes to Veterinary Medicine, P.O. Box 6087, Duluth, MN 55806-6087. Canadian GST Number: R-124213133RT001. Publications Mail Agreement Number: 40612608. Return undeliverable Canadian addresses to: IMEX Global Solutions, P.O. Box 25542, London, ON N6G 6B2, Canada. Printed in the U.S.A. © 2015 UBM Life Sciences. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical including by photocopy, recording, or information storage and retrieval without permission in writing from the publisher. Authorization to photocopy items for internal/educational or personal use, or the internal/educational or personal use of specific clients is granted by UBM Life Sciences for libraries and other users registered with the Copyright Clearance Center, 222 Rosewood Dr. Danvers, MA 01923, 978-750-8400 fax 978-646-8700 or visit <http://www.copyright.com> online. For uses beyond those listed above, please direct your written request to Permission Dept. fax 440-756-5255 or email: [mcannon@advanstar.com](mailto:mcannon@advanstar.com). UBM Life Sciences provides certain customer contact data (such as customers' names, addresses, phone numbers, and e-mail addresses) to third parties who wish to promote relevant products, services, and other opportunities which may be of interest to you. If you do not want UBM Life Sciences to make your contact information available to third parties for marketing purposes, simply call toll-free (866) 529-2922 between the hours of 7:30 a.m. and 5 p.m. CST and a customer service representative will assist you in removing your name from UBM Life Sciences' lists. Outside the United States, please call (218) 740-6477. Veterinary Medicine does not verify any claims or other information appearing in any of the advertisements contained in the publication, and cannot take responsibility for any losses or other damages incurred by readers in reliance on such content. Publisher assumes no responsibility for unsolicited manuscripts, photographs, art, and other material. Unsolicited material will not be returned. Address correspondence to Veterinary Medicine, 8033 Flint, Lenexa, KS 66214; (913) 871-3800; e-mail [vm@advanstar.com](mailto:vm@advanstar.com). To subscribe, call toll-free 888-527-7008. Outside the U.S. call 218-740-6477.

# High-frequency sounds can lead to seizures in some older cats

## Why they did it

Researchers in the United Kingdom, aware of the occurrence of seizures induced in cats exposed to sounds at certain frequencies, sought to characterize feline audiogenic reflex seizures (FARS) to provide a description of this previously unreported syndrome.

## What they did it

Cases of suspected FARS were solicited from primary veterinarians and owners through print media, the Internet and the radio. Cat pedigrees, medical histories and cheek swab DNA samples were collected. A detailed online questionnaire was made available to those owners whose cats met the inclusion criteria. A full medical history and, in many cases, video recordings of episodes were also reviewed.

The questionnaire asked about signalment, precipitating factors, the cat's overall health and any relevant therapies or medications as well as detailed descriptions of the episodes. It was designed to avoid leading owners to make conclusions or to provide "expected answers."

For inclusion in the study, the cats had to have suffered three or more generalized tonic-clonic seizures (GTCSs) precipitated by the same sound and lasting less than five minutes for a minimum one-year history. Other types of episodes such as myoclonic seizures or jerks and absence seizures were described separately on the questionnaire. A total of 96 cats met the criteria for the study.

## What they found

The mean age for seizure onset was 15, with a fairly even distribution of males and females. Many breeds were represented, but Birman cats were most common ( $n=30$ ). The noise stimulus for all cats was high-pitched, and audiogenic kindling—repeated sound stimulation resulting in progression from myoclonic seizures to GTCS—was observed in most of the subjects. The seizure episodes occurred an average of once every three to six months, and of the cats in which diagnostics were pursued, no cause for the seizures was found.

Some common sounds that induced FARS episodes in affected cats were

- Crinkling tin foil ( $n=82$ )
- Dropping a metal spoon into a ceramic bowl ( $n=79$ )
- Clinking or tapping a glass ( $n=72$ )
- Crinkling paper or plastic bags ( $n=71$ )
- Typing on a computer keyboard or clicking a mouse ( $n=61$ )

Many of the cats had concurrent disease, most commonly chronic renal disease and hyperthyroidism. None of the cats demonstrated progression of the seizure disorder. Interestingly, 50% of the cats were described as having hearing loss or deafness. Forty-four cats received antiseizure medication—phenobarbital or levetiracetam—to control their seizures, but only levetiracetam resulted in good control of both the myoclonic seizures and GTCSs.

## Take-home message

FARS is newly defined nonprogressive clinical syndrome affecting geriatric cats

characterized by myoclonic seizures and GTCSs triggered by high-pitched sounds, often with persistence of the sound serving to increase the severity of the seizure episode. Levetiracetam appears to be more effective than phenobarbital in controlling both the myoclonic seizures and GTCSs associated with FARS. Birman cats were over-represented in this study, suggesting a breed predilection and genetic basis for the disorder. Hearing loss or deafness reported in many of these cats may not indicate damage to the area of the cochlea associated with higher frequency hearing, providing an explanation for how FARS occurs in cats with apparent hearing impairment or deafness. **VM**

**Lowrie M, Bessant C, Harey RJ, et al. Audiogenic reflex seizures in cats. *J Feline Med Surg* 2015; epub ahead of print.**





# Treating otitis externa just got easier.

Just two doses per ear,  
dosed one week apart

done.

The simple treatment for otitis externa\*, with easy application.

- Just two doses per ear, dosed one week apart
- Same dose for every dog
- Single-dose tube with soft, flexible tip is gentle on a dog's ears
- Easy application may lead to better compliance

Ask your Elanco Animal Health sales representative about OSURNIA today.



**NEW**

## Osurnia®

(florfenicol • terbinafine • betamethasone acetate)

### Important Safety Information

OSURNIA® (florfenicol/terbinafine/betamethasone acetate) is for otic use only under veterinary supervision. Do not use in dogs with known tympanic perforation or a hypersensitivity to florfenicol, terbinafine or corticosteroids. Adverse reactions observed during clinical trials include vomiting, increased liver enzymes and transient loss of hearing. Please see brief summary on page 258 for additional information.

\*Associated with susceptible strains of bacteria (*Staphylococcus pseudintermedius*) and yeast (*Malassezia pachydermatis*).

© 2015 Elanco. OSURNIA®, Elanco® and the diagonal bar are all trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates. USCACOSU00001-2



## Osurnia®

(florfenicol-terbinafine-betamethasone acetate)

### Otic gel

Antibacterial, antifungal, anti-inflammatory

### For Otic Use in Dogs Only

**Before using this product, please consult the product insert, a summary of which follows:**

#### Caution:

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

**Indication:** OSURNIA is indicated for the treatment of otitis externa in dogs associated with susceptible strains of bacteria (*Staphylococcus pseudintermedius*) and yeast (*Malassezia pachydermatis*).

**Contraindications:** Do not use in dogs with known tympanic perforation (see **Precautions**). Do not use in dogs with a hypersensitivity to florfenicol, terbinafine or corticosteroids.

**Warnings:** Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. In case of accidental skin contact, wash area thoroughly with water. Avoid contact to the eyes.

**Precautions:** Do not administer orally. The use of OSURNIA in dogs with perforated tympanic membranes has not been evaluated. The integrity of the tympanic membrane should be confirmed before administering this product. Reevaluate the dog if hearing loss or signs of vestibular dysfunction are observed during treatment. Use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hyperadrenocorticism in dogs. Use with caution in dogs with impaired hepatic function. The safe use of OSURNIA in dogs used for breeding purposes, during pregnancy, or in lactating bitches, has not been evaluated.

**Adverse Reactions:** The most common adverse reactions reported during the course of a US field study for treatment of otitis externa in dogs treated with OSURNIA with 1 tube per affected ear(s) and repeated after 7 days were Elevated Alkaline Phosphatase, Vomiting, and Elevated AST, ALT, ALP\* \*Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP). Two dogs with pre-existing elevations in ALP were reported to have an increase in liver enzymes (ALP, ALT and/or AST) at study exit. Subsequent clinical chemistries returned to pre-treatment levels in one dog, while no follow up was performed for the second dog.

To report suspected adverse drug events, contact Elanco Animal Health at 1-800-332-2761. For additional information about adverse drug experience reporting for animal drugs, contact the FDA at 1-888-FDA-VETS or <http://www.fda.gov/AnimalVeterinary/SafetyHealth>. For technical assistance, contact Elanco Animal Health at 1-800-332-2761.

#### Effectiveness:

Effectiveness was evaluated in 235 dogs with otitis externa. The study was a double-masked field study with a placebo control (vehicle without the active ingredients). 159 dogs were treated with OSURNIA and 76 dogs were treated with the placebo control. All dogs were evaluated for safety. Treatment (1 mL) was administered to the affected ear(s) and repeated 7 days later. Prior to the first administration, the ear(s) were cleaned with saline but not prior to the Day 7 administration. Six clinical signs associated with otitis externa were evaluated: pain, erythema, exudate, swelling, odor and ulceration. Total clinical scores were assigned for a dog based on the severity of each clinical sign on Days 0, 7, 14, 30 and 45. Success was determined by clinical improvement at Day 45. The success rates of the two groups were significantly different ( $p=0.0094$ ); 64.78% of dogs administered OSURNIA were successfully treated, compared to 43.42% of the dogs in the placebo control group.

NADA # 141-437, Approved by FDA  
© 2013 Novartis Animal Health US, Inc.  
OSURNIA is a registered trademark of Novartis AG

**Manufactured for:** Novartis Animal Health US, Inc., Greensboro, NC 27408 USA  
Eli Lilly and Company has purchased the Novartis Animal Health business to be combined with Elanco, Lilly's animal health division.

Made in UK

NAH/OSU-GEL/BS/2

 **NOVARTIS**  
ANIMAL HEALTH

## JOURNAL SCAN

# Ovarian pedicle tie technique put to the test

## Why they did it

Since time is always of the essence, these researchers evaluated the rate of hemorrhage-related complications associated with pedicle tie procedures in cats undergoing ovariohysterectomy at the Oregon Humane Society (OHS) and compared the surgical time of pedicle tie to the pedicle double ligation technique.

## What they did

The study involved two phases. In phase one, more than 2,000 intact female cats were spayed with the pedicle tie technique by one of three surgeons experienced with the procedure. The cats, which were either part of a low-cost spay-neuter program or owned by the OHS and adopted shortly after surgery, were categorized as kittens (< 4 months of age) or adults (> 4 months of age). Cats in estrus or that were pregnant were not excluded from the study as they were routinely spayed in this clinic setting.

The cats were evaluated for ovarian pedicle hemorrhage intraoperatively and monitored postoperatively. Any hemorrhagic complications were corrected either at the time of surgery or via exploratory surgery if hemorrhage was suspected after recovery.

In phase two, the surgical times were recorded for more than 200 similarly categorized female intact cats undergoing ovariohysterectomy with either the pedicle tie or pedicle double ligation technique.

## What they found

Of the large number of pedicle tie procedures performed in phase one, only six ovarian pedicle hemorrhagic complications were recorded. Five of these were detected intraoperatively and corrected via pedicle ligation. None of these were cats in estrus or pregnant, and the surgical times for the pedicle tie procedure were two minutes faster than with pedicle double ligation technique.

## Take-home message

For practices with limited resources performing a high volume of feline ovariohysterectomies, every minute counts. The results of this study suggest that the pedicle tie procedure is associated with a low risk of ovarian pedicle hemorrhage while reducing surgical time. The benefits of a two-minute per surgery time reduction in a high-volume spay and neuter clinic are significant considering employee (surgeon and anesthetist) pay and anesthetic and surgical material (suture) cost savings over time. Furthermore, the reduced surgical time may also decrease the risk for other types of surgery-related complications such as hypothermia or infection. **VM**

**Miller K, Rekers W, Ellis K, et al. Pedicle ties provide a rapid and safe method for feline ovariohysterectomy. J Feline Med Surg 2015; Epub ahead of print.**

*These "Journal Scan" summaries were contributed by Avi Blake, DVM, a freelance technical editor and writer in Eudora, Kansas.*

# exceptional continuing education

that supports the way you practice  
veterinary medicine today



**SAN  
DIEGO**  
DECEMBER  
3-6, 2015

**Register today at [TheCVC.com](http://TheCVC.com),  
or call 800.255.6864, ext. 6.**

“You’re going to learn and  
laugh along the way.  
It’s a lot like dealing with real clients.”

**CVC San Diego Speaker, Andrew Roark, DVM, MS**  
about his dvm360 Full Circle sessions “The angry client experience.”

**CALL** 800.255.6864, ext. 6 **CLICK** [TheCVC.com](http://TheCVC.com) **EMAIL** [cvc@advanstar.com](mailto:cvc@advanstar.com) **FOLLOW**





# Submandibular *draining tracts* in a Maltese mix

By Kendall Taney, DVM, DAVDC



**A** 4-year-old spayed female Maltese mix was presented for chronic bilateral draining tracts and swelling below the mandibles. Treatment with multiple courses of antibiotics was not successful in resolving the lesions. An oral examination revealed some abnormalities with the shape and crowns of the mandibular first molars.

**Which of the following is the most likely diagnosis?**

- a) Rubber jaw
- b) Carious lesions of the first mandibular molars
- c) Dens invaginatus
- d) Complicated crown fractures of 309 and 409
- e) Neoplasia

(See the answer on page 262.)





>>> 1. Bilateral chronic draining tracts on the ventral aspect of the lower jaw.

>>> 2. Crown shape and surface abnormalities of the left mandibular first molar. The same abnormalities were noted on the right.

>>> 3. The normal first mandibular molar roots are divergent. After elevation of a mucogingival flap and lateral alveolar bone removal, these tooth roots appear to be converging.

>>> 4. A dental radiograph of left mandibular first molar (309).

>>> 5. A dental radiograph of right mandibular first molar (409).





## Oral Suspension for Cats

Veraflox (pradofloxacin) Oral Suspension for Cats  
25 mg/mL

For the treatment of skin infections (wounds and abscesses) in cats. Do not use in dogs.

### BRIEF SUMMARY:

Before using Veraflox Oral Suspension for Cats, please consult the product insert, a summary of which follows:

### CAUTION:

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

### PRODUCT DESCRIPTION:

Pradofloxacin is a fluoroquinolone antibiotic and belongs to the class of quinolone carboxylic acid derivatives. Each mL of Veraflox Oral Suspension provides 25 mg of pradofloxacin.

### INDICATIONS:

Veraflox is indicated for the treatment of skin infections (wound and abscesses) in cats caused by susceptible strains of *Pasteurella multocida*, *Streptococcus canis*, *Staphylococcus aureus*, *Staphylococcus felis*, and *Staphylococcus pseudintermedius*.

### CONTRAINDICATIONS:

**DO NOT USE IN DOGS.** Pradofloxacin has been shown to cause bone marrow suppression in dogs. Dogs may be particularly sensitive to this effect, potentially resulting in severe thrombocytopenia and neutropenia. Quinolone-class drugs have been shown to cause arthropathy in immature animals of most species tested, the dog being particularly sensitive to this side effect. Pradofloxacin is contraindicated in cats with a known hypersensitivity to quinolones.

### HUMAN WARNINGS:

**Not for human use. Keep out of reach of children.** Individuals with a history of quinolone hypersensitivity should avoid this product. Avoid contact with eyes and skin. In case of ocular contact, immediately flush eyes with copious amounts of water. In case of dermal contact, wash skin with soap and water for at least 20 seconds. Consult a physician if irritation persists following ocular or dermal exposure or in case of accidental ingestion. In humans, there is a risk of photosensitization within a few hours after exposure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight. Do not eat, drink or smoke while handling this product. For customer service or to obtain product information, including a Material Safety Data Sheet, call 1-800-633-3796. For medical emergencies or to report adverse reactions, call 1-800-422-9874.

### ANIMAL WARNINGS:

**For use in cats only.** The administration of pradofloxacin for longer than 7 days induced reversible leukocyte, neutrophil, and lymphocyte decreases in healthy, 12-week-old kittens.

### PRECAUTIONS:

The use of fluoroquinolones in cats has been associated with the development of retinopathy and/or blindness. Such products should be used with caution in cats. Quinolones have been shown to produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species. The safety of pradofloxacin in cats younger than 12 weeks of age has not been evaluated. The safety of pradofloxacin in immune-compromised cats (i.e., cats infected with feline leukemia virus and/or feline immune-deficiency virus) has not been evaluated. Quinolones should be used with caution in animals with known or suspected central nervous system (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation that may lead to convulsive seizures. The safety of pradofloxacin in cats that are used for breeding or that are pregnant and/or lactating has not been evaluated.

### ADVERSE REACTIONS:

In a multi-site field study, the most common adverse reactions seen in cats treated with Veraflox were diarrhea/loose stools, leukocytosis with neutrophilia, elevated CPK levels, and sneezing.

### ANIMAL SAFETY:

In a target animal safety study in 32, 12-week-old kittens dosed at 0, 1, 3, and 5 times the recommended dose for 21 consecutive days. One 3X cat and three 5X cats had absolute neutrophil counts below the reference range. The most frequent abnormal clinical finding was soft feces. While this was seen in both treatment and control groups, it was observed more frequently in the 3X and 5X kittens.

U.S. Patent No. 6,323,213

May, 2012

84364593/84364607, R.O

NADA141-344, Approved by FDA

Made in Germany

Bayer, the Bayer Cross and Veraflox are registered trademarks of Bayer.


GHG021815

**Bayer**

Bayer HealthCare LLC  
Animal Health Division

Shawnee Mission, Kansas 66201, U.S.A.

## IMAGE QUIZ



## Answer

### c) Dens invaginatus

Dens invaginatus is a developmental abnormality in which the enamel organ infolds back into the tooth as the permanent tooth is forming. These teeth often have dentin exposure and do not have normal root canal systems, and pulp necrosis occurs soon after eruption.

A histopathologic examination is needed to definitively diagnose the condition, but the appearance of the crown, root and endodontic system can provide strong support for the diagnosis of dens invaginatus. Abnor-

malities of the crown can be evident, and enamel may be rough or irregular in the area of the furcation.

Radiographs reveal that the roots are converging together instead of diverging as they normally would. The endodontic system may also be difficult to define or may be obstructed in areas.

Treatment options include endodontic treatment or extraction. Endodontic treatment can be challenging since often the root canal system is not normal and the canals can be difficult to navigate and treat effectively. If you suspect this condition in a patient, endodontic therapy can be initiated to prevent

pulp death and subsequent infection.

In this case, there is significant periapical bone loss due to the chronic infection. Careful extraction of these teeth is warranted to prevent pathologic mandibular fracture.

The prognosis is good for stability and strength of the mandible once bony healing occurs. Use of a bone graft in the alveolus may help facilitate the healing process. **VM**

*Kendall Taney, DVM, DAVDC, is a partner at the Center for Veterinary Dentistry and Oral Surgery in Gaithersburg, Maryland.*





Veraflox® (pradofloxacin)  
Oral Suspension for Cats



**Engineered for cats.**  
Without compromise.



**Veraflox®**  
(pradofloxacin)

Oral Suspension for Cats

E f f i c a c y      S a f e t y      E a s e - o f - u s e

See brief summary on page 262

**Find out more at [VerafloxOS.com](http://VerafloxOS.com)**


CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra label use of this drug in food-producing animals. WARNINGS: For use in cats only. PRECAUTIONS: The safety of pradofloxacin in cats younger than 12 weeks of age has not been evaluated.

©2015 Bayer HealthCare LLC, Animal Health, Shawnee Mission, Kansas 66201. Bayer, the Bayer Cross and Veraflox are registered trademarks of Bayer.

V15413

# At-home diabetic monitoring How much should you *charge*?

**A**t-home blood glucose monitoring has become a valuable tool clinically, often generating a more accurate picture of how a pet is doing than when curves are performed in the clinic. Inspired by their upcoming Learn Then Earn session at CVC San Diego, Dec. 3, veterinary endocrinologist Dr. David Bruyette and financial consultant Dr. Karen Felsted have a frank talk about the best way to charge—or not charge—clients for consultations while they're performing at-home monitoring for their diabetic pets.

 Watch the video by scanning the QR code on the left or by visiting [dvm360.com /diabetescharge](http://dvm360.com/diabetescharge).

Then read fellow CVC San Diego veterinary endocrinology speaker Dr. Ellen Behrend's pointers on at-home glucose monitoring.



## Love what you hear?

See Drs. Bruyette and Felsted live in CVC San Diego, Dec. 3-6. Visit [thecvc.com/sd](http://thecvc.com/sd) for more details and to register.

## The particulars on at-home blood glucose monitoring

By Ellen N. Behrend, VMD, MS, PhD, DACVIM

**T**o avoid some of the problems associated with in-hospital blood glucose curves, performance of glucose curves at home has taken on new importance. Home curves are likely the most accurate.

For home glucose curves, it is not necessary for venous blood to be collected. Capillary blood is suitable.<sup>1</sup> Choices of sites are the ear, gum, footpads or elbow callus (dogs). I do not recommend using the gum and foot-

pads because of the associated pain. Keep in mind that glucose curves can vary from day to day when done at home as well.<sup>2</sup>

Two types of lancing devices are available. If using conventional automatic devices



1.8 mg/mL

For subcutaneous use in cats

**BRIEF SUMMARY:** Before using SIMBADOL, please consult the full prescribing information, a summary of which follows.

**CAUTION:** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

#### HUMAN SAFETY WARNING

##### Abuse Potential

**SIMBADOL contains buprenorphine (1.8 mg/mL), an opioid agonist and Schedule III controlled substance with an abuse potential similar to other Schedule III opioids. Buprenorphine has certain opioid properties that in humans may lead to dependence of the morphine type. Abuse of buprenorphine may lead to physical dependence or psychological dependence. The risk of abuse by humans should be considered when storing, administering and disposing of SIMBADOL. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (suicidal depression).**

##### Life-Threatening Respiratory Depression

**Respiratory depression, including fatal cases, may occur with abuse of SIMBADOL.**

##### Additive CNS Depressant Effects

**SIMBADOL has additive CNS depressant effects when used with alcohol, other opioids, or illicit drugs that cause central nervous system depression.**

##### Accidental Exposure

**Because of the potential for adverse reactions associated with accidental injection, SIMBADOL should only be administered by veterinarians or veterinary technicians who are trained in the handling of potent opioids.**

**See Human Safety for detailed information.**

**INDICATION:** SIMBADOL is indicated for the control of postoperative pain associated with surgical procedures in cats.

**DOSAGE AND ADMINISTRATION:** The dosage of SIMBADOL is 0.24 mg/kg (0.11 mg/lb) administered subcutaneously once daily, for up to 3 days. Administer the first dose approximately 1 hour prior to surgery. Do not dispense SIMBADOL for administration at home by the pet owner (see Human Safety).

**CONTRAINDICATIONS:** SIMBADOL is contraindicated in cats with known hypersensitivity to buprenorphine hydrochloride or any of the components of SIMBADOL, or known intolerance to opioids.

**WARNINGS:** For subcutaneous (SQ) injectable use in cats.

##### Human Safety: Not for use in humans. Keep out of reach of children.

Because of the potential for adverse reactions, hospital staff should avoid accidental exposure and contact with skin, eyes, oral or other mucous membrane during administration. SIMBADOL contains buprenorphine, a mu opioid partial agonist and Schedule III controlled substance with an abuse potential similar to other Schedule III opioids. SIMBADOL can be abused and is subject to misuse, abuse, addiction and criminal diversion. SIMBADOL should be handled appropriately to minimize the risk of diversion, including restriction of access, the use of accounting procedures, and proper disposal methods, as appropriate to the clinical setting and as required by law. Abuse of SIMBADOL poses a hazard of overdose and death. This risk is increased with concurrent abuse of alcohol and other substances including other opioids and benzodiazepines. Buprenorphine has been diverted for non-medical use into illicit channels of distribution. All people handling opioids require careful monitoring for signs of abuse. Drug abuse is the intentional non-therapeutic use of a prescription drug for its rewarding psychological or physiological effects. Abuse of opioids can occur in the absence of true addiction. Naloxone may not be effective in reversing respiratory depression produced by buprenorphine. The onset of naloxone effect may be delayed by 30 minutes or more. Doxapram hydrochloride has also been used as a respiratory stimulant.

**PRECAUTIONS:** Hyperactivity (opioid excitation) has been observed up to 8 hours after anesthetic recovery (see ADVERSE REACTIONS). Safety has not been evaluated in moribund cats. Use in such cases should be based on the risk-benefit assessment of the veterinarian. Use with caution in cats with impaired hepatic function. The use of SIMBADOL has not been evaluated in breeding, pregnant, or lactating cats, or in cats younger than 4 months of age.

**ADVERSE REACTIONS:** In two controlled field studies, the following adverse reactions were reported.

Adverse Reactions in Two Field Studies				
Adverse Reaction <sup>a</sup>	SIMBADOL (N = 224)		Control (N = 226)	
	During Surgery <sup>b</sup>	After Surgery	During Surgery <sup>b</sup>	After Surgery
Hypotension <sup>c</sup>	68 (30.4%)	51 (22.8%)	60 (26.5%)	40 (17.7%)
Tachycardia <sup>d</sup>	55 (24.6%)	73 (32.6%)	30 (13.3%)	44 (19.5%)
Hypothermia ( $\leq 98.0^{\circ}\text{F}$ )	38 (17.0%)	1 (0.4%)	47 (20.8%)	0
Hyperthermia ( $\geq 103.0^{\circ}\text{F}$ )	1 (0.4%)	91 (40.6%)	0	33 (14.6%)
Hypertension <sup>e</sup>	10 (4.5%)	40 (17.9%)	17 (7.5%)	18 (8.0%)
Anorexia	0	40 (17.9%)	0	35 (15.5%)
Hyperactivity	0	26 (11.6%)	0	11 (4.9%)
Reduced SpO <sub>2</sub> ( $\leq 90\%$ )	8 (3.6%)	1 (0.4%)	11 (4.9%)	0
Bradycardia ( $\leq 90$ beats/min)	5 (2.2%)	1 (0.4%)	4 (1.8%)	1 (0.4%)
Tachypnea ( $\geq 72$ breaths/min)	0	5 (2.2%)	1 (0.4%)	6 (2.7%)
Arrhythmia	1 (0.4%)	1 (0.4%)	2 (0.9%)	0
Blindness	0	2 (0.9%)	0	1 (0.4%)
Apnea/Death	1 (0.4%)	1 (0.4%)	0	0
Ataxia	0	1 (0.4%)	0	0
Hyperesthesia	0	1 (0.4%)	0	0

a. Cats may have experienced more than one type or occurrence of an adverse reaction. Cats experiencing the same reaction both during and after surgery are presented in both time periods.

b. During surgery is the time from the administration of the anesthetic induction agent until discontinuation of the gas anesthetic.

c. Hypotension is defined as a mean blood pressure of  $\leq 60$  mmHg during surgery and  $\leq 90$  mmHg after surgery.

d. Tachycardia is defined as a heart rate of  $\geq 180$  beats per minute during surgery and  $\geq 200$  beats per minute after surgery.

e. Hypertension is defined as a mean blood pressure of  $\geq 120$  mmHg during surgery and  $\geq 160$  mmHg after surgery.

To report suspected adverse events, contact Abbott Animal Health at 1-888-299-7416, FDA at 1-888-FDA-VETS or FDA online at <http://www.fda.gov/AnimalVeterinary/SafetyHealth>.

**EFFECTIVENESS:** The effectiveness of SIMBADOL was demonstrated in two randomized, masked, placebo-controlled, multi-site field studies involving client-owned cats of various breeds. A descriptive, interactive pain assessment system was used by the trained assessor over the 72-hour post-operative period to determine pain control, and treatment success was defined as a cat that completed the 72-hour post-operative period without rescue analgesia. A statistically significant difference ( $P \leq 0.005$ ) in the number of successes in the treatment group over the placebo control group was observed. The results of two field studies demonstrate that SIMBADOL is effective and has an acceptable safety margin for the control of postoperative pain in cats.

**HOW SUPPLIED:** SIMBADOL (buprenorphine injection) is supplied in a carton containing one 10 mL amber glass vial. Each multidose vial contains 1.8 mg/mL of buprenorphine.

NADA 141-434, Approved by FDA

SIMBADOL is a trademark of Abbott Laboratories.

Manufactured for: Abbott Laboratories, North Chicago, IL 60064 USA

Product of United Kingdom



# Q&A on New Pain Management Guidelines

In May 2015, the American Animal Hospital Association (AAHA) and the American Association of Feline Practitioners (AAFP) issued new pain management guidelines for dogs and cats. Zoetis, maker of SIMBADOL™ (buprenorphine injection), asked Dr. Michael Petty, DVM, of Arbor Pointe Veterinary Hospital in Canton, Michigan, and one of the authors of the new guidelines, about what's new in the updated guidelines and about surgical pain management for cats.

---

**Q** Why was there a need to update the pain management guidelines for dogs and cats?

**A** The last guidelines were published eight years ago, and since 2007 the profession has developed a much better understanding of pain medications and how they are used in veterinary medicine. The new guidelines also give much more specific information on uses, doses and indications for the pain medications available to veterinarians.

**Q** How do the new guidelines address pain management for cats?


**A** Dogs and cats can exhibit pain in different ways. For example, dogs limp, but cats rarely do. Pain in cats is often exhibited by a change in behavior, such as an unwillingness to jump, use the litter box or interact with people.

A lot of older cats are seen as cranky, but they wouldn't be cranky if they weren't in pain. We treat the pain, and suddenly the owners have a happy cat again.

---

**Q** Looking specifically at surgery, what do you see as the most significant change in surgical pain management for cats over the past few years?

**A** When I was in veterinary school, we were told never to use opioids in cats. Since then, there has been a lot of research presented in the literature and it has become an accepted practice. Also, the guidelines approach pain management with a multimodal view and provide information on what drugs are safe to use in combination.



# & Feline Surgical Pain with Dr. Mike Petty

**Q** Are there particular points that veterinarians should take into account when considering surgical pain management for cats?

**A** Veterinarians can re-evaluate their anesthesia protocols, and if they are not addressing pain appropriately, then I suggest that they start out slowly with one analgesic, such as SIMBADOL. It's such a no-brainer of a drug; give it once, and it lasts for 24 hours with very good pain control. Once a doctor is comfortable, add in NSAIDs or local anesthetics.

**Q** Are there any other important points regarding surgical pain management in cats that veterinarians should consider?

**A** Practitioners should consider employing a pain management scale for each and every cat they see. Just looking at a cat isn't enough. You have to measure it. You can't know if the cat is running a fever without a thermometer, and you can't tell if a cat is in pain without using a pain scale.

**Q** What medications would you recommend a veterinarian have in his or her "toolkit" for managing surgical pain in cats? Why are these medications important?

**A** I recommend SIMBADOL because I know through personal use how effective and safe it is; plus, it is the only long-lasting opioid approved for cats.



I also suggest meloxicam because of its strong anti-inflammatory effects as well as local anesthetics because they are so safe, easy to use and block 100 percent of the pain. If veterinarians are using those three things, they are doing a great job of managing feline pain.



## IMPORTANT SAFETY INFORMATION

**WARNINGS, PRECAUTIONS and CONTRAINDICATIONS:** Due to serious human safety and abuse concerns, including physical or psychological dependence, life-threatening respiratory depression and additive CNS depressant effects, read the full prescribing information before using this drug, including the complete Boxed Warning. Not for use in humans. Hospital staff should be trained in the handling of potent opioids and should avoid accidental exposure.

For subcutaneous (SQ) injectable use in cats. Opioid excitation has been observed up to 8 hours after anesthetic recovery. Use with caution in cats with impaired hepatic function. SIMBADOL has not been evaluated in breeding, pregnant, or lactating cats, in cats younger than 4 months of age or moribund cats. Do not use in cats with known hypersensitivity to buprenorphine hydrochloride or any of the components of SIMBADOL, or known intolerance to opioids.

**ADVERSE REACTIONS:** In two controlled field studies, the most frequent adverse reactions with SIMBADOL were hypotension, tachycardia, hypothermia, hyperthermia, hypertension, anorexia and hyperactivity. Less frequent but serious adverse reactions included two deaths following apnea and two reports of presumptive post-anesthetic cortical blindness. See the full prescribing information for a complete list and additional details of adverse reactions for each field study.

**See full Prescribing Information on page 265, including the complete Boxed Warning for human safety.**

Dr. Petty is a consultant for Zoetis.

 **Simbadol™**   
(buprenorphine injection)

## Side tip:

The purpose of a glucose curve is to determine how a particular dose of insulin is performing given a specific diet and schedule. Thus, routine must be adhered to. A normal routine is difficult to maintain even if the dog or cat is being “poked” every two hours at home. However, the standard procedures must be adhered to as much as possible.

designed for pricking human fingertips, choose a device with a variable needle depth. The appropriate depth for each patient can then be used.<sup>3</sup> A needle can be used, especially if the marginal ear vein is the site of blood collection. Glucometers that require minimal amounts of blood as well as those that sip the blood into the strip are desirable.

Training owners to perform home glucose curves takes time. Not all owners are suited to perform such a task. A small study of nine owners of diabetic dogs (n=7) and cats (n=2) indicated that, at least in that population, the most frequently encountered problems were the need for more than one puncture to obtain a blood drop, the creation of a sufficient blood drop, the need

for assistance in restraining the pet, and the pet's resistance.<sup>4</sup> Two dogs became more resistant over time, and the owners abandoned the technique. The two cats became more compliant, especially because the technique was performed in a place chosen by the cat.<sup>4</sup> **VM**

## References

1. Casella M, Wess G, Hassig M, et al. Home monitoring of blood glucose concentration by owners of diabetic dogs. *J Small Anim Pract* 2003;44(7):298-305.
2. Alt N, Kley S, Haessig M, et al. Day-to-day variability of blood glucose concentration curves generated at home in cats with diabetes mellitus. *J Am Vet Med Assoc* 2007;230(7):1011-1017.
3. Reusch CE, Wess G, Casella M. Home monitoring of blood glucose concentration in the management of diabetes mellitus. *Compend Contin Educ Pract Vet* 2001;23:544-556.
4. Van de Maele I, Rogier N, Daminet S. Retrospective study of owners' perception on home monitoring of blood glucose in diabetic dogs and cats. *Can Vet J* 2005;46(8):718-723.

See more tips for diabetic cat owners from Dr. Behrend at [dvm360.com/diabetestips](http://dvm360.com/diabetestips).

# Getting clients on board

Download the client handouts “My dog has diabetes—now what?” and “My cat has diabetes—now what?” at [dvm360.com/diabeteshandout](http://dvm360.com/diabeteshandout).

And find out how the whole veterinary team can send diabetic pets home with confidence at [dvm360.com/diabetesconfidence](http://dvm360.com/diabetesconfidence).





# From Eureka to Action

## Why and How to Create a Fear-Free Practice

Dr. Marty Becker is on a mission to make Fear-Free veterinary visits a reality for pets. He's outspoken about the need, and his message is eye-opening. In this symposium, you'll learn how to use Fear-Free concepts to:

- put animals and owners at ease
- deliver a higher level of compassionate care
- earn repeat visits.

You will also receive a copy of the new brochure

*"Top 10 Ways to Get Started with Fear-Free Veterinary Visits."*

### Marty Becker, DVM

*Fear-Free tools to transform patient interactions, boost visits, and enhance your practice.*

### Richard LeCouteur, BVSC, PhD, DACVIM (Neurology), DECVN

*The science of fear in animals: It's real. It's damaging. It's our responsibility.*

### Lisa Radosta, DVM, DACVB

*Fear-Free techniques: Clinical behavioral evidence that they work.*

### Jonathan Bloom, DVM

*Modern love — Making pets happy at the veterinary hospital.*



Saturday, December 5, 2015

\*7:15 AM - 12:20 PM

San Diego Convention Center

Visit [TheCVC.com](http://TheCVC.com) for details.

\*Eye Opener Breakfast will open at 6:45 AM.

Proud sponsors of the **Fear-Free** Initiative



# Fipronil toxicosis *in* rabbits

At one time, spot-on topical fipronil formulations for dogs and cats were recommended for extralabel use in rabbits, but no more. Exposure to these products can cause life-threatening signs in rabbits. *By Laura A. Stern, DVM*

**F**ipronil is a phenylpyrazole insecticide used to control a variety of insects such as ants, beetles, cockroaches, fleas, ticks and termites. It comes in a variety of formulations: topical, spray, dust and bait. This article focuses on the topical spot-on product labeled for use in dogs and cats. When this product initially debuted, published, extralabel dosing recommendations for fipronil were used successfully in rabbits,<sup>1,2</sup> but subsequently, extralabel administration in rabbits has become contraindicated due to toxicity concerns.<sup>2,3</sup>

## Pharmacokinetics and metabolism

Dermal absorption of topically applied fipronil in rabbits is low at 0.07%. Oral absorption is higher at 30% to 50% of the ingested dose and is possible if the rabbit licks the product off after topical application.<sup>4</sup> Fipronil is detected on the hair and superficial skin layers but not in the dermis or hypodermis.<sup>5</sup> It accumulates in the sebaceous gland and then is released by the follicular ducts.

## Mechanism of action

Fipronil blocks GABA receptors in the central nervous system, which leads to the prevention of chloride ion uptake and results in excessive central nervous system stimulation and death. Fipronil exhibits a greater affinity for binding insect GABA receptors than for binding mammalian GABA receptors,

resulting in a wide margin of safety for most mammals while still causing death to insects.<sup>4</sup>

## Toxicity

The no observed adverse effect level (NOAEL) for rabbits is 5 mg/kg/day when applied topically.<sup>4</sup> Topically applied fipronil is classified as moderately toxic for rabbits.<sup>6</sup> The dermal LD<sub>50</sub> for rabbits is 354 mg/kg.<sup>6</sup>

In one study, 10 mg/kg/day of fipronil applied topically to rabbits for 21 days caused decreases in mean body weight, weight gain and food consumption.<sup>4</sup> Other studies have shown that dermal dosing in rabbits causes hypersalivation, tremors, hyperactivity, diarrhea, emaciation and death.<sup>6</sup> Delays in the appearance of signs were noted in these studies. Seizures were not seen until three to nine days after exposure, and death often occurred 11 to 14 days after



exposure.<sup>6</sup> Young rabbits have been reported to be more sensitive to the effects of fipronil than older rabbits are.<sup>3,7</sup>

### ASPCA Animal Poison Control Center data

A review of the ASPCA Animal Poison Control Center's toxicology database from 2003 to 2014 yielded 77 fipronil toxicosis cases involving rabbits.<sup>8</sup> These cases involved exposure to a single agent (fipronil-containing spot-on products used extralabel, inappropriately or erroneously) and were assessed as medium- or high-suspect cases based on the history of exposure and clinical signs. Of the 77 rabbits,

TABLE 1

### Commonly reported clinical signs in rabbits exposed to fipronil\*

Clinical sign	No. of rabbits exhibiting sign	Percentage of rabbits exhibiting sign
Seizures	45	58
Anorexia	44	57
Lethargy	36	47
Hypothermia	7	9
Tremors	5	6
Adipsia	5	6
Ileus	2	3
Agitation	2	3
Hypersalivation	2	3

\*Source: AnTox Database. Urbana, Illinois: ASPCA Animal Poison Control Center, 2003-2014.

## More Berries for the Buck!

At just **half the cost** per tablet of the leading competitor, **CranMate® Nutritional Supplement** is the cost-effective solution for supporting urinary health in your patients.

- Rich in A-type PACs (proanthocyanidins) and antioxidants
- Enhances natural mechanisms for flushing out harmful bacteria
- Free of unwanted sugars and oxalic acid
- Convenient daily dosing of palatable chewable tablets: 1 tablet per 44 lbs.

**Recommend the Best Value in Cranberry Supplements: CranMate**

From the makers of  
**PROIN®**  
(phenylpropanolamine hydrochloride)



**PRN**  
PHARMACAL

800.874.9764 • prnpharmaceutical.com

CranMate®, PRN® and Proin® are registered trademarks of Pegasus Laboratories, Inc. 1/14 03349



# VETORYL® CAPSULES (trilostane)

5 mg, 10 mg, 30 mg, 60 mg and 120 mg strengths

Adrenocortical suppressant for oral use in dogs only.

**BRIEF SUMMARY** (For Full Prescribing Information, see package insert.)

**CAUTION:** Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

**DESCRIPTION:** VETORYL Capsules are an orally active synthetic steroid analogue that blocks production of hormones produced in the adrenal cortex of dogs.

**INDICATION:** VETORYL Capsules are indicated for the treatment of pituitary- and adrenal-dependent hyperadrenocorticism in dogs.

**CONTRAINDICATIONS:** The use of VETORYL Capsules is contraindicated in dogs that have demonstrated hypersensitivity to trilostane. Do not use VETORYL Capsules in animals with primary hepatic disease or renal insufficiency. Do not use in pregnant dogs. Studies conducted with trilostane in laboratory animals have shown teratogenic effects and early pregnancy loss.

**WARNINGS:** In case of overdosage, symptomatic treatment of hypoadrenocorticism with corticosteroids, mineralocorticoids and intravenous fluids may be required. Angiotensin converting enzyme (ACE) inhibitors should be used with caution with VETORYL Capsules, as both drugs have aldosterone-lowering effects which may be additive, impairing the patient's ability to maintain normal electrolytes, blood volume and renal perfusion. Potassium sparing diuretics (e.g. spironolactone) should not be used with VETORYL Capsules as both drugs have the potential to inhibit aldosterone, increasing the likelihood of hyperkalemia.

**HUMAN WARNINGS:** Keep out of reach of children. Not for human use. Wash hands after use. Do not empty capsule contents and do not attempt to divide the capsules. Do not handle the capsules if pregnant or if trying to conceive. Trilostane is associated with teratogenic effects and early pregnancy loss in laboratory animals. In the event of accidental ingestion/overdose, seek medical advice immediately and take the labeled container with you.

**PRECAUTIONS:** Hypoadrenocorticism can develop at any dose of VETORYL Capsules. A small percentage of dogs may develop corticosteroid withdrawal syndrome within 10 days of starting treatment. Mitotane (o,p'-DDD) treatment will reduce adrenal function. Experience in foreign markets suggests that when mitotane therapy is stopped, an interval of at least one month should elapse before the introduction of VETORYL Capsules. The use of VETORYL Capsules will not affect the adrenal tumor itself. Adrenalectomy should be considered as an option for cases that are good surgical candidates. The safe use of this drug has not been evaluated in lactating dogs and males intended for breeding.

**ADVERSE REACTIONS:** The most common adverse reactions reported are poor/reduced appetite, vomiting, lethargy/dullness, diarrhea, elevated liver enzymes, elevated potassium with or without elevated sodium, elevated BUN, decreased Na/K ratio, weakness, elevated creatinine, shaking, and renal insufficiency. Occasionally, more serious reactions, including severe depression, hemorrhagic diarrhea, collapse, hypoadrenocortical crisis or adrenal necrosis/rupture may occur, and may result in death.

 **VETORYL® CAPSULES**  
(trilostane)

Distributed by:  
**Dechra Veterinary Products**  
7015 College Boulevard, Suite 525  
Overland Park, KS 66211


VETORYL is a trademark of  
Dechra Ltd. © 2015, Dechra Ltd.

NADA 141-291, Approved by FDA

  
**Dechra**  
Veterinary Products

## TOXICOLOGY brief

TABLE 2



follow-up was not available for 49 (64%), treatment was still continuing in four (5%), a full recovery was noted in three (4%), and death or euthanasia was observed in 21 (27%).<sup>8</sup>

The most commonly reported clinical signs observed in this review were seizures, anorexia, lethargy, hypothermia, tremors, adipsia, ileus, agitation and hypersalivation (*Table 1*). The gastrointestinal signs and depression often, but not always, preceded the tremors and seizures.<sup>8</sup>

The onset of seizures was often markedly delayed from the exposure, starting as soon as a couple hours after exposure to as long as 20 days later (*Table 2*). In one case, mild seizures lasted several weeks.<sup>8</sup>

### Monitoring

Monitor the patient's food and water intake, as anorexia and adipsia are common. Also monitor the patient for changes in body temperature, tremors and seizure activity.

### Treatment

Bathing the rabbit with liquid dish-washing detergent within 48 hours of the exposure will easily remove the fipronil.<sup>9</sup> After 48 hours, bathing is probably minimally effective. Special care should be taken to keep the rabbit warm during and after bathing until its fur is fully dry.

Benzodiazepines, such as diazepam (1 to 3 mg/kg intramuscularly or intravenously) or midazolam (1 to 2 mg/kg intramuscularly or intravenously), can be given to treat seizure-like activity.<sup>10</sup> For patients with seizures lasting longer than 48 hours, levetiracetam therapy can be initiated (20 mg/kg orally t.i.d., potentially for a few weeks).<sup>11</sup>

Maintenance fluids (100 to 120 ml/kg/day) should be administered to maintain the patient's hydration.<sup>11</sup> Nutritional support, such as Critical Care (Oxbow Animal Health; 10 to 15 ml/kg orally b.i.d. to t.i.d.), may be indicated in anorectic rabbits.<sup>11</sup> Often, inappetent rabbits may consume this

**They may be small,  
but their treatment is now mighty.**



**VETORYL® Capsules (trilostane)  
are now available in a 5mg strength.**

Your smaller patients can now receive the same effective, FDA-approved treatment for their Cushing's syndrome as you've trusted for your larger patients.

**VETORYL Capsules** are the only FDA approved pharmaceutical for the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism in dogs (Cushing's syndrome). They contain the active ingredient trilostane, which blocks the excessive production of cortisol.

As with all drugs, side effects may occur. In field studies and post-approval experience, the most common side effects reported were: anorexia, lethargy/depression, vomiting, diarrhea, elevated liver enzymes, elevated potassium with or without elevated sodium, elevated BUN, decreased Na/K ratio, hypoadrenocorticism, weakness, elevated creatinine, shaking, and renal insufficiency. In some cases, death has been reported as an outcome of these adverse events. VETORYL Capsules are not for use in dogs with primary hepatic or renal disease, or in pregnant dogs. Refer to the prescribing information for complete details or visit [www.Dechra-US.com](http://www.Dechra-US.com).



**24 Hour Technical Support: 866-933-2472 | [www.dechra-us.com](http://www.dechra-us.com) | [support@dechra.com](mailto:support@dechra.com)**

VETORYL is a trademark of Dechra LTD. ©2015, Dechra Ltd.  
NADA 141-291, Approved by FDA

See brief summary on page 272

CAUTION: Federal law restricts this drug to use by or on the order of licensed veterinarian.  
\*<http://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm049823.htm>

Dechra Veterinary Products US and the Dechra D logo are registered trademarks of Dechra Pharmaceuticals PLC.

*The onset of seizures may be greatly delayed, so at-home monitoring for several weeks after exposure is warranted.*



View the references for this article online at [dvm360.com/fipronilrabbit](http://dvm360.com/fipronilrabbit).

voluntarily, but force feeding with a syringe may be indicated when continued feed refusal is present. If the rabbit is hypothermic, provide an external heat source, such as a heating pad or warming blanket.

### Conclusion

Fipronil has a narrow margin of safety in rabbits. Its administration is contraindicated because of the potential for life-threatening signs and the availability of safer alternative spot-on

products for external parasite control.

Seizures, anorexia, adipsia and lethargy are common clinical signs in rabbits exposed to

topical fipronil products. The onset of seizures may be greatly delayed in these patients, and at-home monitoring for the development of seizures for several weeks after exposure is warranted. Mild seizures may last for several weeks. The prognosis is guarded for all rabbits exhibiting seizures.<sup>9</sup> **VM**

Laura A. Stern, DVM  
ASPCA Animal Poison Control Center  
1717 S. Philo Road, Suite 36  
Urbana, IL 61802

## Loxicom® (meloxicam) 1.5 mg/mL Oral Suspension

Non-steroidal anti-inflammatory drug for oral use in dogs only

**Warning:** Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats. See Contraindications, Warnings, and Precautions for detailed information.

**Brief Summary:** Before using Loxicom Oral Suspension, consult the product insert, a summary of which follows.

**Caution:** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

**Description:** Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class.

**Indications:** Loxicom Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

**Contraindications:** Dogs with known hypersensitivity to meloxicam should not receive Loxicom Oral Suspension. **Do not use Loxicom Oral Suspension in cats. Acute renal failure and death have been associated with the use of meloxicam in cats.**

**Warnings:** Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. **For oral use in dogs only.** As with any NSAID all dogs should undergo a thorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to and periodically during administration. To report suspected adverse reactions, to obtain a Material Safety Data Sheet, or for technical assistance, call Norbrook at 1-866-591-5777.

**Precautions:** The safe use of Loxicom Oral Suspension in dogs younger than 6 months of age, dogs used for breeding, or in pregnant or lactating dogs has not been evaluated. As a class,

cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed. Since NSAIDs possess the potential to induce gastrointestinal ulcerations and/or perforations, concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided or closely monitored. The use of concomitantly protein-bound drugs with Loxicom Oral Suspension has not been studied in dogs. Commonly used protein-bound drugs include cardiac, anticonvulsant and behavioral medications. The influence of concomitant drugs that may inhibit metabolism of Loxicom Oral Suspension has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy.

**Adverse Reactions:** Field safety was evaluated in 306 dogs. Based on the results of two studies, GI abnormalities (vomiting, soft stools, diarrhea, and inappetence) were the most common adverse reactions associated with the administration of meloxicam. Of the dogs that took meloxicam (n=157), forty experienced vomiting, nineteen experienced diarrhea/soft stool, five experienced inappetence, and one each experienced bloody stool, bleeding gums after dental procedure, lethargy/swollen carpus, and epiphora. Of the dogs that took the placebo (n=149), twenty-three experienced vomiting, eleven experienced diarrhea/soft stool, and one experienced inappetence. In foreign suspected adverse drug reaction (SADR) reporting over a 9 year period, incidences of adverse reactions related to meloxicam administration included: auto-immune hemolytic anemia (1 dog), thrombocytopenia (1 dog), polyarthritis (1 dog), nursing puppy lethargy (1 dog), and pyoderma (1 dog).

**Effectiveness:** The effectiveness of meloxicam was demonstrated in two field studies involving a total of 277 dogs representing various breeds, between six months and six-

teen years of age, all diagnosed with osteoarthritis. Both of the placebo-controlled, masked studies were conducted for 14 days. All dogs received 0.2 mg/kg on day 1. All dogs were maintained on 0.1 mg/kg oral meloxicam from days 2 through 14 of both studies. Parameters evaluated by veterinarians included lameness, weight-bearing, pain on palpation, and overall improvement. Parameters assessed by owners included mobility, ability to rise, limping, and overall improvement. In the first field study (n=109), dogs showed clinical improvement with statistical significance after 14 days of meloxicam treatment for all parameters. In the second field study (n=48), dogs receiving meloxicam showed a clinical improvement after 14 days of therapy for all parameters; however, statistical significance was demonstrated only for the overall investigator evaluation on day 7, and for the owner evaluation on day 14.

**How Supplied:** Loxicom Oral Suspension 1.5 mg/mL: 10, 32 and 100 mL bottles with small and large dosing syringes.

**Storage:** Store at controlled room temperature 68-77°F (20-25°C).

Excursions permitted between 59°F and 86°F (15°C and 30°C). Brief exposure to temperature up to 104°F (40°C) may be tolerated provided the mean kinetic temperature does not exceed 77°F (25°C); however such exposure should be minimized.

Made in the UK.

Manufactured by:

Norbrook Laboratories Limited  
Newry, BT35 6PU, Co. Down, Northern Ireland

Loxicom® is a registered trademark  
of Norbrook Laboratories Limited





# Bad hips and knees:

## Is it hip dysplasia *or* a torn cruciate ligament?

It can be difficult to differentiate between these two orthopedic problems. Luckily, the sit test, among other diagnostic evaluations, can help. *By Jennifer Wardlaw, DVM, MS, DACVS*

**D**ifferentiating between a torn cruciate ligament and hip dysplasia can be tricky, if not frustrating. In one study, 32% of dogs referred to a surgeon for hip dysplasia treatment actually had a torn cranial cruciate ligament.<sup>1</sup> Let's review the differences between the two conditions and how simply asking a dog to "sit" offers great clues.

### CRANIAL CRUCIATE LIGAMENT TEAR

The severity of lameness depends on the severity of ligament disruption. For dogs with stable partial tears, lameness can be subtle and noted only after periods of strenuous activity. For dogs with complete tears, lameness will initially be severe and non-weight-bearing. Then, moderate to severe weight-bearing lameness will occur.

Rupture of the contralateral cruciate ligament occurs in 37%

to 48% of dogs within six to 17 months of the initial diagnosis.<sup>1</sup> However, ruptures can be bilateral on presentation, giving affected dogs what appears to be a neurologic, crouched walk.

In obvious cases, the keys to diagnosing cranial cruciate rupture are a positive cranial drawer sign and tibial thrust. But what about less obvious cases?

### Physical examination

Orthopedic examination reveals various degrees of stifle pain with flexion and extension, variable crepitus, and possibly clicking associated with a meniscal tear.


In patients with partial tears, a pain response is elicited when the joint is in full extension. In patients with chronic cases, muscle atrophy is notable, and periarticular fibrosis (medial buttress) is evident on the medial side of the stifle. Medial buttress is almost pathognomonic

for a cranial cruciate rupture. The only other condition that may present with a medial buttress is a medial collateral ligament tear, which is usually seen with a deranged stifle, not with simple lameness.

Joint effusion is also a key finding. It can be palpated on the medial and lateral aspects of the patellar tendon.

In patients with a partial tear, the cranial drawer sign may or may not be present. An examination performed while the patient is sedated is needed to confirm the findings. Many patients that do not seem to have a cranial drawer sign while awake have one once they are sedated and relaxed.

Find out how "Sit. Good dog!" can aid you in your orthopedic evaluations.





**>>> 1.** This dog's abnormal sitting position—extending its leg rather than flexing its knee—indicates that it has a cruciate ligament tear, not hip dysplasia.



**>>> 2A.** Cranial tibial thrust is evident on this radiograph (loss of visualization of the infrapatellar fat pad shadow and caudal displacement of the gastrocnemius fascial plane), but this tibia is subluxated.



**>>> 2B.** Joint effusion is appreciated on this radiograph (loss of visualization of the infrapatellar fat pad shadow and caudal displacement of the gastrocnemius fascial plane), but this tibia is positioned normally without subluxation.

### Sit test

Dogs with a torn cruciate ligament sit abnormally. For example, notice how the patient in *Figure 1* does not want to flex its right knee. Affected dogs often sit with the affected leg extending out to the side rather than sitting squarely, which they will do even with hip dysplasia. So noting how the dog sits is a critical part of an evaluation.

### Imaging

Radiography is warranted in all suspected cases to document stifle arthritis, confirm pathology in challenging cases of partial tears and rule out other disorders (e.g. tumors). The earliest, most consistent finding is the loss of an infrapatellar fat pad shadow by a soft tissue opacity in the lateral view, which is consistent with effusion. Caudal displacement of the gastrocnemius fascial plane, located caudal to the joint capsule by a soft tissue opacity, is also consistent with synovial distention.

In many cases, you can see the cranial tibial thrust on a radiograph (*Figure 2A*). Compare this with the position of the second radiograph, which also has effusion but the tibia is not displaced into a cranial position (*Figure 2B*). Another consistent finding is osteophyte or enthesiophyte formation in the region of femoral trochlear ridges and tibial plateau and at the base and apex of the patella.

### HIP DYSPLASIA

Hip dysplasia causes joint inflammation and secondary osteoarthritis, which lead to variable degrees of pain. Clinical signs can vary from slight discomfort to severe acute or chronic pain. Although the disease onset has a linear progression over time, it can be divided into two forms.


The juvenile form typically affects dogs between 5 and 12 months of age. Affected dogs may present with unilateral or bilateral hindlimb lameness or pain on hip extension. Affected dogs may be bunny hopping at presentation, have difficulty rising after rest, exhibit exercise intolerance, or seem reluctant to walk, run, jump or climb stairs. These clinical signs are the result of joint laxity and resultant instability and inflammation.

The chronic form of hip dysplasia has a highly variable onset of clinical signs in middle-aged to senior dogs. Pain is most often related to degenerative joint disease and has a more severe presentation. Clinical signs are similar to the juvenile form. Pain is elicited most notably during hip extension. Patients tend to off load their hip joints by shifting weight forward onto their thoracic limbs. Because of weight shifting over a long period of time, muscle atrophy of the hindlimbs is common. In large dogs, you can often see

muscular hypertrophy of the forelimbs as a result of the dogs' chronically hauling themselves up by their forelimbs.

## Imaging

As the disease progresses, crepitus can be palpated with range of motion manipulation. An examination while the patient is sedated, followed by orthogonal radiography will further support the diagnosis of hip dysplasia. While the more chronic cases are much easier to diagnose on radiographs and physical examination (Figures 3A & 3B),



>>> 3A. Mild hip dysplasia often has incongruence, acetabular sclerosis and a thickened Morgan's line where the joint capsule inserts along the femoral neck.

>>> 3B. Severe hip dysplasia is more easily seen and felt on physical examination. Radiographs confirm arthritic changes and help planning for surgery.

younger dogs can often be challenging on radiographs. Since you may not have bony arthritic changes on these films, assess-

ing for laxity in your physical examination and radiographs is vital for young dog diagnosis (Figures 4A & 4B).

### Brief Summary of Prescribing Information

## convenia® (cefovecin sodium)

Antimicrobial for Subcutaneous Injection in Dogs and Cats Only  
**CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.**

#### INDICATIONS:

##### Dogs

CONVENIA is indicated for the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of *Staphylococcus intermedius* and *Streptococcus canis* (Group G).

##### Cats

CONVENIA is indicated for the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of *Pasteurella multocida*.

**CONTRAINDICATIONS:** CONVENIA is contraindicated in dogs and cats with known allergy to cefovecin or to  $\beta$ -lactam (penicillins and cephalosporins) group antimicrobials. Anaphylaxis has been reported with the use of this product in foreign market experience. If an allergic reaction or anaphylaxis occurs, CONVENIA should not be administered again and appropriate therapy should be instituted. Anaphylaxis may require treatment with epinephrine and other emergency measures, including oxygen, intravenous fluids, intravenous antihistamine, corticosteroids, and airway management, as clinically indicated. Adverse reactions may require prolonged treatment due to the prolonged systemic drug clearance (65 days).

**WARNINGS: Not for use in humans. Keep this and all drugs out of reach of children.** Consult a physician in case of accidental human exposure. For subcutaneous use in dogs and cats only. Antimicrobial drugs, including penicillins and cephalosporins, can cause allergic reactions in sensitized individuals. To minimize the possibility of allergic reactions, those handling such antimicrobials, including cefovecin, are advised to avoid direct contact of the product with the skin and mucous membranes.

**PRECAUTIONS:** Prescribing antibacterial drugs in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to treated animals and may increase the risk of the development of drug-resistant animal pathogens.

The safe use of CONVENIA in dogs or cats less than 4 months of age and in breeding or lactating animals has not been determined. Safety has not been established for IM or IV administration. The long-term effects on injection sites have not been determined. CONVENIA is slowly eliminated from the body, approximately 65 days is needed to eliminate 97% of the administered dose from the body. Animals experiencing an adverse reaction may need to be monitored for this duration.

CONVENIA has been shown in an experimental *in vitro* system to result in an increase in free concentrations of carprofen, furosemide, doxycycline, and

ketoconazole. Concurrent use of these or other drugs that have a high degree of protein-binding (e.g., NSAIDs, propofol, cardiac, anticonvulsant, and behavioral medications) may compete with cefovecin-binding and cause adverse reactions.

Positive direct Coombs' test results and false positive reactions for glucose in the urine have been reported during treatment with some cephalosporin antimicrobials. Cephalosporin antimicrobials may also cause falsely elevated urine protein determinations. Some antimicrobials, including cephalosporins, can cause lowered albumin values due to interference with certain testing methods.

Occasionally, cephalosporins and NSAIDs have been associated with myelotoxicity, thereby creating a toxic neutropenia\*. Other hematological reactions seen with cephalosporins include neutropenia, anemia, hypoprothrombinemia, thrombocytopenia, prolonged prothrombin time (PT) and partial thromboplastin time (PTT), platelet dysfunction and transient increases in serum aminotransferases.

#### ADVERSE REACTIONS:

##### Dogs

A total of 320 dogs, ranging in age from 8 weeks to 19 years, were included in a field study safety analysis. Adverse reactions reported in dogs treated with CONVENIA and the active control are summarized in Table 2.

**Table 2: Number of Dogs\* with Adverse Reactions Reported During the Field Study with CONVENIA.**

Adverse Reaction	CONVENIA (n=157)	Active Control (n=163)
Lethargy	2	7
Anorexia/Decreased Appetite	5	8
Vomiting	6	12
Diarrhea	6	7
Blood in Feces	1	2
Dehydration	0	1
Flatulence	1	0
Increased Borborygmi	1	0

\*Some dogs may have experienced more than one adverse reaction or more than one occurrence of the same adverse reaction during the study.

Mild to moderate elevations in serum  $\gamma$ -glutamyl trans-ferase or serum alanine aminotransferase were noted post-treatment in several of the CONVENIA-treated dogs. No clinical abnormalities were noted with these findings.

One CONVENIA-treated dog in a separate field study experienced diarrhea post-treatment lasting 4 weeks. The diarrhea resolved.

##### Cats

A total of 291 cats, ranging in age from 2.4 months (1 cat) to 21 years, were included in the field study safety analysis. Adverse reactions reported in cats treated with CONVENIA and the active control are summarized in Table 3.

**Table 3: Number of Cats\* with Adverse Reactions Reported During the Field Study with CONVENIA.**

Adverse Reaction	CONVENIA (n=157)	Active Control (n=163)
Vomiting	10	14
Diarrhea	7	26
Anorexia/Decreased Appetite	6	6
Lethargy	6	6
Hyper/Acting Strange	1	1
Inappropriate Urination	1	0

\*Some cats may have experienced more than one adverse reaction or more than one occurrence of the same adverse reaction during the study.

Four CONVENIA cases had mildly elevated post-study ALT (1 case was elevated pre-study). No clinical abnormalities were noted with these findings.

Twenty-four CONVENIA cases had normal pre-study BUN values and elevated post-study BUN values (37-38 mg/dL post-study). There were 6 CONVENIA cases with normal pre- and mildly to moderately elevated post-study creatinine values. Two of these cases also had an elevated post-study BUN. No clinical abnormalities were noted with these findings.

One CONVENIA-treated cat in a separate field study experienced diarrhea post-treatment lasting 42 days. The diarrhea resolved.

**FOREIGN MARKET EXPERIENCE:** The following adverse events were reported voluntarily during post-approval use of the product in dogs and cats in foreign markets: death, tremors/ataxia, seizures, anaphylaxis, acute pulmonary edema, facial edema, injection site reactions (alopecia, scabs, necrosis, and erythema), hemolytic anemia, salivation, pruritus, lethargy, vomiting, diarrhea, and inappetence.

**For a copy of the Material Safety Data Sheet (MSDS) or to report a suspected adverse reaction call Zoetis Inc. at 1-888-963-8471.**

#### STORAGE INFORMATION:

Store the powder and the reconstituted product in the original carton, refrigerated at 2° to 8° C (36° to 46° F). Use the entire contents of the vial within 56 days of reconstitution. PROTECT FROM LIGHT. After each use it is important to return the unused portion back to the refrigerator in the original carton. As with other cephalosporins, the color of the solution may vary from clear to amber at reconstitution and may darken over time. If stored as recommended, solution color does not adversely affect potency.

#### HOW SUPPLIED:

CONVENIA is available as a 10 mL multi-use vial containing 800 milligrams of cefovecin as a lyophilized cake.

NADA# 141-285, Approved by FDA

**zoetis**

Distributed by  
Zoetis Inc.  
Kalamazoo, MI 49007

January 2013  
PAA035845A&P



STATEMENT OF OWNERSHIP,  
MANAGEMENT, AND CIRCULATION  
(Requester Publications Only)  
(Required by 39 USC 3685)

1. Publication Title: Veterinary Medicine
2. Publication Number: 8750-7943
3. Filing Date: 9/30/15
4. Issue Frequency: Monthly
5. Number of Issues Published Annually: 12
6. Annual Subscription Price (if any): \$60.00
7. Complete Mailing Address of Known Office of Publication:  
131 West First Street, Duluth, St. Louis County,  
Minnesota 55802-2065  
Contact Person: Kristina Bildeaux  
Telephone: 507-895-6758
8. Complete Mailing Address of Headquarters or  
General Business Office of Publisher:  
2450 Colorado Avenue, Suite 300, Santa Monica, CA 90404
9. Full Names and Complete Mailing Addresses of  
Group Publisher: Becky Turner Chapman, 8033 Flint, Lenexa  
KS 66214  
Sales Director: David Doherty, 8033 Flint, Lenexa KS 66214  
Content Manager: Adrienne Wagner, 8033 Flint, Lenexa, KS 66214
10. This publication is owned by: Advanstar Communications  
Inc., 2450 Colorado Avenue, Suite 300, Santa Monica, CA  
90404. The sole shareholder of Advanstar Communications  
Inc. is: Advanstar, Inc., whose mailing address is 2450 Colorado  
Avenue, Suite 300, Santa Monica, CA 90404.
11. Known Bondholders, Mortgages, and Other Security Holders  
Owning or Holding 1 Percent or More of Total Amounts of  
Bonds, Mortgages, or  
Other Securities. If none, check box. ☒ None

12. Does Not Apply

13. Publication Title: Veterinary Medicine

14. Issue Date for Circulation Data Below: August 2015

15. Extent and Nature of Circulation

	Average No. Copies Each Issue During Preceding 12 Months	No. Copies of Single Issue Published Nearest to Filing Date
A. Total Number of Copies	42,519	44,693
B. Legitimate Paid and/or Requested Distribution		
1. Outside County Paid/Requested Mail Subscriptions Stated on PS Form 3541	28,022	29,676
2. In-County Paid/Requested Mail Subscriptions Stated on PS Form 3541	0	0
3. Sales Through Dealers and Carriers, Street Vendors, Counter Sales, and Other Paid or Requested Distribution Outside USPS	387	319
4. Requested Copies Distributed by Other Mail Classes Through the USPS	0	0
C. Total Paid and/or Requested Circulation (Sum of 15b (1), (2), (3), and (4))	28,409	29,995
D. Non-requested Distribution		
1. Outside County Non-requested Copies Stated on PS Form 3541	13,761	14,360
2. In-County Non-requested Copies Stated on PS Form 3541	0	0
3. Non-requested Copies Distributed Through the USPS by Other Classes of Mail	0	0
4. Non-requested Copies Distributed Outside the Mail	278	300
E. Total Non-requested Distribution (Sum of 15d (1), (2), (3) and (4))	14,039	14,660
F. Total Distribution (Sum of 15c and e)	42,448	44,655
G. Copies not Distributed	71	38
H. Total (Sum of 15f and g)	42,519	44,693
I. Percent Paid and/or Requested Circulation	66.93%	67.17%

16. Electronic Copy Circulation

\*If you are not claiming electronic copies, skip to line 17

- A. Requested and Paid Electronic Copies
- B. Total Requested and Paid Print Copies (Line 15C) +  
Requested/Paid Electronic Copies
- C. Total Requested Copy Distribution (Line 15F) +  
Requested/Paid Electronic Copies
- D. Percent Paid and/or Requested Circulation (Both Print &  
Electronic Copies)  
☐ I certify that 50% of all my distributed copies (electronic  
and print) are legitimate requests or paid copies.
17. Publication of Statement of Ownership for a Requester  
Publication is required and will be printed in the October  
issue of this publication.  
Name and Title of Editor, Publisher, Business Manager,  
or Owner:

Kristina Bildeaux, Audience Development Director

*Kristina Bildeaux*

Date: 9/30/15

I certify that the statements made by me above are correct and  
complete.

## ORTHOPEDIC examinations



>>> **4A.** This radiograph was scored as OFA Good with mild incongruence and slight acetabular sclerosis in a young dog.

>>> **4B.** This distracted frog-leg view is of the same dog in Figure 4A but more clearly illustrates the laxity that is present in this patient that was missed with the standard OFA-style radiograph.

torn cruciate ligaments as well since it affects the pain and rehabilitation protocols. In my experience, 80% never need hip surgery, but your knee patients won't do as well if you aren't aware you are fighting two battles.



## CONCLUSION

When evaluating an affected dog, it is imperative to do a thorough orthopedic and neurologic examination to accurately localize the clinical signs and provide an appropriate diagnosis and treatment. My best advice: If you examine the patient and still have doubts about the

diagnosis, sedate the dog and repeat your entire examination (see "7 benefits of sedation" at [dvm360.com/orthosedation](http://dvm360.com/orthosedation)). **VM**

### Acknowledgment

The author would like to thank Dr. Phil Zeltzman for his input in this article.

### Reference

1. Powers MY, Martinez SA, Lincoln JD, et al. Prevalence of cranial cruciate ligament rupture in a population of dogs with lameness previously attributed to hip dysplasia: 369 cases (1994-2003). *J Am Vet Med Assoc* 2005;227(7):1109-1111.

Jennifer Wardlaw, DVM, MS,  
DACVS  
Gateway Veterinary Surgery  
St. Louis, Missouri

## Sit test

Dogs with only hip dysplasia (no concurrent cruciate ligament injury) sit normally, with both legs flexed symmetrically.

## DOUBLE TROUBLE

Of course, both conditions can be present in a dog at the same time. In the study mentioned above, 32% of dogs referred to a surgeon for hip dysplasia treatment had a torn cranial cruciate ligament.<sup>1</sup> Interestingly, 94% of the dogs with a cruciate tear had concurrent radiographic signs of hip dysplasia.<sup>1</sup>

Thus, I think it is a great practice to radiograph the hips in patients with

DENTAL PRODUCTS

LEBALAB

Search

**LEBA III™**

## Have you Discovered Leba III?

100% Response in Double Blind Tests  
See the Results on [www.lebalab.com](http://www.lebalab.com)

35 Days Later



Before

After

28 Days Later



Before

After



## Cleans Teeth with the Ease of a Spray

The LebaLab difference:

Leba III stimulates the good flora in the saliva. The longer Leba III is used, the cleaner the teeth and the healthier the chemistry of the mouth becomes. Antibacterial products kill the good bacteria in the mouth leading to imbalance and repeated dental procedures.

Pets ingest dental products, they cannot rinse. They can become subject to the side effects of the components, that's why Leba III contains no Grapefruit Seed Extract, no chlorides or chemical agents.

Used by veterinarians since 1994.

**To order, call toll free: 1-866-532-2522**

[www.lebalab.com](http://www.lebalab.com) | [tellus@lebalab.com](mailto:tellus@lebalab.com) | Questions? Call 1-519-542-4236

**LebaLab Inc.**



Search for the company name you see in each of the ads in this section for FREE INFORMATION!



## VETERINARY BUYERS GROUPS


THE VETERINARY  
COOPERATIVE

Search

# Join us!

## Independent veterinarians thrive by working together!


### Just ask our members!



Rebates &  
Discounts

"I joined TVC a year ago and hoped I'd save some money. I did not expect the rebate check that arrived last week. I actually called TVC to make sure this was for real! This year I am going to use TVC even more as I now have proof that the savings are significant and this really works! Thanks TVC!"

*Helen Green, DVM  
Owner, Mission Valley Pet Clinic, San Diego, CA*



Revenue  
Enhancing  
Programs

"I didn't think this Revenue Enhancing Program was going to be profitable. But today, about 10% of my clients are now participating and it is the most profitable segment of my business on a percentage basis. The Pet Food Program also keeps patients healthy with the best nutrition and coming to my clinic often."

*Peter Hartman, DVM  
Owner, Valley Lakes Veterinary Clinic, Round Lake, IL*



TVC  
University

"TVC University provides me the expertise and ability to generate income, leaving me to concentrate on being a veterinarian in the exam room and surgery suite. I have come to depend on TVC University programs put together by the TVC staff to help me maximize profits by finding the best strategy on the business side of my clinic."

*Daniel L Otto DVM  
Owner, Superior Veterinary Care, Lincoln NE*










The Hive

"The Hive is a new feature at TVC. I love having the ability to get questions about promotions and programs answered and I can ask questions, too. It's great to see the group come together to help a member if they have a challenging business situation or a medical case. It's like having a close colleague...well, hundreds of close colleagues...who are just a mouse-click away!"

*Laura Betts, DVM  
Owner, Parkdale Animal Hospital Manistee, MI*

### Join The Veterinary Cooperative— run by veterinarians for veterinarians and experience the benefits

-  No monthly fee, no annual fee, no long term commitments
-  Discounts and rebates that allow you to compete
-  Increase revenue and profit with member-tested programs
-  Get help and advice from other members
-  Use only the vendors helpful to your clinic
-  You do not buy anything from TVC
-  Over 1,000 clinics strong nationwide

### Join today!

**\$100** NEW  
MEMBER  
SPECIAL

One-time (lifetime) fee.

30 day FREE trial.

Go to [www.tvc.coop/vme1015](http://www.tvc.coop/vme1015)

Offer expires Nov. 15, 2015





## ANESTHESIA EQUIPMENT

**BLUEPRINT  
FOR BREATHING**Anesthesia made simple... **A.D.S. 2000**Proudly made in  
the U.S.A.**Revolutionary Veterinary Breakthrough**

- Anesthesia Machine (Positive Pressure)
- Electronically microprocessor controlled
- Delivery & Ventilation for small animal use
- Automatically sets breathing parameters
- Very affordable and easy to use
- Just connect to vaporizer & Oxygen
- Two year parts & labor warranty
- Free lifetime loaner service

**NEWLY ADDED  
FEATURE !!!**12 Hour Battery  
backup providing  
portability and protection**engler**  
engineering  
corporation**In Business  
Since 1964**

1099 East 47th Street - Hialeah, Florida 33013 USA

**800-445-8581 - FAX 305-685-7671****www.englerusa.com**

## MEDICAL EQUIPMENT

CALL US FOR A  
**FREE SAMPLE****BiteNot**  
The collar that cares**The Comfortable Alternative  
to the Elizabethan Cone**— Available from Distributors —  
Call us for a free sample.**1-800-424-8366**[www.bitenot.com](http://www.bitenot.com)**dvm360.com**

## DIAGNOSTIC TESTING

**NOSORB™****Easy Urine Collection from Cats**


- Nonabsorbent cat litter
- Comes in urine cup
- Easily dispensed or used in hospital
- Clients love it
- Inexpensive, bulk 5lb. tub with scoop
- Readily accepted by cats
- Inert—will not affect test results
- Recommended and used by Veterinary urologists at many Veterinary teaching hospitals

**Available through your Veterinary Distributor, or contact:****CATCO, 140 SE 23rd St., Cape Coral, FL 33990 for information**Visit our Web Site at [HTTP://www.bpsom.com/catco/catco.htm](http://www.bpsom.com/catco/catco.htm) for distributor information.

## TAGS

**TAGS**

- Available in Colored Aluminum, Brass or Stainless Steel
- Dog & Cat Heart Styles
- Order by Oct. 15 to ensure delivery before Jan. 1

Click or  
call to order!**859-261-2035****National Band & Tag Company**  
INTERNATIONAL IDENTIFICATION INC.

Family Operated Since 1902

[tags@nationalband.com](mailto:tags@nationalband.com)  
[www.nationalband.com](http://www.nationalband.com)

## VETERINARY POSITIONS AVAILABLE

**IDAHO**


Emergency/Small Animal Veterinarian wanted in the panhandle of Idaho. Experience required. Full or part-time available. The successful applicant will work nights, weekends, and holidays with very flexible scheduling at a privately owned four year old emergency clinic. Company is growing into a referral center and needs ethical team players focused on high quality medicine. 6,000 square foot building is equipped with digital x-ray, ultrasound, endoscopy, complete in-house laboratory, crematory, blood bank, and Internal Medicine Specialist. CE stipend, medical insurance, licensing, dues, and discounts provided. Base pay with no commission. Come enjoy beautiful mountains, lakes, and outdoor activities. E-mail [annie@emergencypetcare.org](mailto:annie@emergencypetcare.org)

**dvm360**  
Find it all here.**Get more product  
information online****Place your  
ad here**Get your message to  
veterinarians and team  
members **TODAY**.Call Angela Paulovcin at  
(800)225-4569, ext. 2629  
[apaulovcin@advanstar.com](mailto:apaulovcin@advanstar.com)

## Keep *trash* out of sight with **cat doors**

To hide our trash cans inside our cabinets, we installed cat doors with magnetized closures (PetSafe). Since the doors are plastic, they are easy to clean compared with laminated doors, and the size is perfect for a hand to fit through and throw things away. On one cabinet we installed two doors—one for trash and one for used syringes—labeling each opening appropriately.

*Dr. Robert Dumont  
Laval, Quebec, Canada*



**We need your ideas!**  
We'll pay \$50 for regular submissions and \$75 for videos that we publish in print or online.

Email [vm@advanstar.com](mailto:vm@advanstar.com), fax us at (913) 273-9876, or write to Idea Exchange Editor at 8033 Flint, Lenexa, KS 66214.



## **Rubber bands** keep blood pressure cuffs in place

We cut indentations into our shelving unit to better suit our storage needs. To store our blood pressure cuffs, we place them upright in a large indentation and stretch a rubber band in front.

*Dr. Robert Dumont  
Laval, Quebec, Canada*



### **New Mind Over Miller online!**



#### **Interns from afar**

Dr. Miller worked with several interns from other countries throughout his veterinary career. Read about some of his favorite adventures with them at [dvm360.com/miller](http://dvm360.com/miller).

### **Also online...**



Dr. Rudayna Ghubash helps you match the right demodicosis treatment to the right patient at [dvm360.com/DemodexTx](http://dvm360.com/DemodexTx).



**NOW  
AVAILABLE!**

**Loxicom<sup>®</sup>**  
(meloxicam)

1.5 mg/mL Oral Suspension

**Keep Your Patients  
Running Back To You**

**FDA-Approved Loxicom<sup>®</sup> (meloxicam) Oral Suspension  
For Dogs:**

- Contains the same active ingredient and is bioequivalent to Metacam<sup>®</sup> (meloxicam) Oral Suspension
- Priced to keep your clients coming back to your clinic for prolonged OA therapy
- When asked what would motivate clients to visit their veterinarian more often, the top 3 responses were **cost** related\*
- Available in convenient 10 mL, 32 mL and 100 mL bottles with small and large syringes calibrated for accurate dosing



**Loxicom Injection  
ALSO AVAILABLE!**



**Loxicom Oral Suspension for Dogs ...  
Keep them Running Back For More**

\*Source: Bayer Veterinary Care Usage Study III, 2013

Observe label directions. **Do not use Loxicom Oral Suspension in cats. Acute renal failure and death have been associated with the use of meloxicam in cats.** As with any medication, side effects may occur. These are usually mild, but may be serious. The most common side effects reported in field studies were vomiting, soft stool/diarrhea and decreased appetite. If side effects occur, discontinue treatment immediately and consult a veterinarian. Dogs should be evaluated for pre-existing medical conditions prior to treatment and monitored during therapy. See product labeling for full product information.

[www.norbrookinc.com](http://www.norbrookinc.com)

The Norbrook logos and Loxicom are registered trademarks of Norbrook Laboratories Limited  
Metacam is a registered trademark of Boehringer Ingelheim Vetmedica, Inc.  
0715-497-1018

**Norbrook<sup>®</sup>**

See brief summary on page 274



Photos: Kerri Slomcenski, DVM

# One and done.

In a U.S. efficacy study, 86% of dogs needed only one injection to resolve their skin infection.<sup>1</sup>

**Baseline**

**10 days post-injection**

**Recommend CONVENIA® (cefovecin sodium) for first-time resolution of bacterial skin infections.**

**[convenia.com](http://convenia.com)**



Three-year-old mixed breed diagnosed with facial moist dermatitis treated with CONVENIA 8 mg/kg

**IMPORTANT SAFETY INFORMATION:** People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to CONVENIA. Do not use in dogs or cats with a history of allergic reactions to penicillins or cephalosporins. Side effects for both dogs and cats include vomiting, diarrhea, decreased appetite/anorexia and lethargy. See Brief Summary of full Prescribing Information on page 277

<sup>1</sup>Six R, Cherni J, Chesebrough R, et al. Efficacy and safety of cefovecin in treating bacterial folliculitis, abscesses, or infected wounds in dogs. *J Am Vet Med Assoc.* 2008;233(3):433-9.

All trademarks are the property of Zoetis Inc., its affiliates and/or its licensors.  
©2015 Zoetis Inc. All rights reserved. October 2015. AIF-00286D

**zoetis**